[Review] Systemic light chain and transthyretin amyloidosis—treatment advancements and future directions | ClinicLens
Once rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly treatable. Basic scientific discoveries regarding the molecular mechanisms of transthyretin misfolding and aggregation have driven the development of drugs
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.